Supplementary figure 1. Time outline of study of polyphenols and breast cancer survival in the European Prospective Investigation into Cancer (EPIC) cohort. Initially 367,903 women were part of the cohort, of which 11,782 women were diagnosed with breast cancer. In this study, the women with breast cancer were followed from the date of diagnosis of breast cancer until death (all-cause or breast cancer-specific death), last date of contact or end of follow-up. The median time since diagnosis was 6 years.

Supplementary table 1. Quartile estimates of the association between estimated intake of polyphenol classes with all-cause mortality and breast cancer specific mortality according to menopausal status among women diagnosed with breast cancer – The European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Premenopausal / Postmenopausal
Endpoint / All-cause mortality / BC-specific mortality / All-cause mortality / BC-specific mortality
Increment/range / HR
(95% CI) / HR
(95% CI) / HR
(95% CI) / HR
(95% CI)
Cases/deceased / 2,804/295 / 2,804/186 / 8,978/1,187 / 8,978/567
Flavonoids
Adjusted for lifestyle and clinical factors (model 3)‡
Quartile 1‡ / ≤271 / 1.00
Ref. / 1.00
Ref. / 1.00
Ref. / 1.00
Ref.
Quartile 2‡ / 271 to ≤444 / 0.88
(0.60 –1.29) / 1.16
(0.71–1.91) / 0.88
(0.73–1.06) / 0.79
(0.60–1.02)
Quartile 3‡ / 444 to ≤ 705 / 1.09
(0.73 –1.61) / 1.24
(0.74–2.10) / 1.08
(0.89–1.30) / 1.00
(0.76–1.32)
Quartile 4‡ / >705 / 0.82
(0.53 –1.28) / 1.14
(0.63–2.04) / 0.95
(0.76–1.17) / 0.82
(0.60–1.12)
Phenolic acids
Adjusted for lifestyle and clinical factors (model 3)‡
Quartile 1‡ / ≤333 / 1.00
Ref. / 1.00
Ref. / 1.00
Ref. / 1.00
Ref.
Quartile 2‡ / 333 to ≤ 539 / 1.17
(0.82–1.67) / 1.25
(0.81–1.92) / 1.04
(0.88–1.23) / 0.99
(0.78–1.26)
Quartile 3‡ / 539 to ≤793 / 0.95
(0.66–1.38) / 1.04
(0.67–1.63) / 0.91
(0.76–1.09) / 1.00
(0.77–1.29)
Quartile 4‡ / >793 / 1.05
(0.71–1.57) / 0.98
(0.58–1.67) / 0.93
(0.76–1.13) / 0.89
(0.65–1.20)
Stilbenes
Adjusted for lifestyle and clinical factors (model 3)‡
Quartile 1‡ / ≤0.1 / 1.00
Ref. / 1.00
Ref. / 1.00
Ref. / 1.00
Ref.
Quartile 2‡ / 0.1 to ≤ 0.6 / 0.98
(0.67–1.43) / 0.87
(0.54–1.40) / 0.82
(0.68–0.99) / 0.97
(0.75–1.26)
Quartile 3‡ / 0.6 to ≤ 2.2 / 0.77
(0.51–1.17) / 0.90
(0.53–1.52) / 0.83
(0.68–1.02) / 0.82
(0.61–1.10)
Quartile 4‡ / >2.2 / 0.95
(0.56–1.64) / 1.03
(0.50–2.13) / 0.80
(0.62–1.02) / 0.87
(0.60–1.26)
Lignans
Adjusted for lifestyle and clinical factors (model 3)‡
Quartile 1‡ / ≤1.1 / 1.00
Ref. / 1.00
Ref. / 1.00
Ref. / 1.00
Ref.
Quartile 2‡ / 1.1 to ≤1.4 / 1.30
(0.89–1.91) / 1.35
(0.82–2.22) / 0.74
(0.74–1.04) / 0.91
(0.71–1.16)
Quartile 3‡ / 1.4to ≤ 2.0 / 1.09
(0.72–1.65) / 1.08
(0.62–1.86) / 0.82
(0.68–0.99) / 0.66
(0.50–0.87)
Quartile 4‡ / >2.0 / 1.63
(1.03–2.57) / 1.72
(0.96–3.09) / 0.86
(0.70–1.06) / 0.72
(0.53–0.98)
‡Model 3: Adjusted for lifestyle factors including alcohol (abstainer and intake g/day), BMI, HRT use, Schooling, smoking status, physical activity index, and the polyphenol classes are further adjusted for intake of other polyphenol classes (mutual adjustment).and also the following clinical factors: ER receptor status, cancer stage and grading of tumor. Further, strata are made for country and 5-year age group
HR; hazard rate, 95%CI; 95% confidence intervals, ER; estrogen receptor HRT; hormone replacement therapy